BPC-157 in 2026: FDA status, legal access, dosage and side effects
What changed with HHS’s October 2026 policy, what a lawful prescription involves, and how thin the human evidence is.
BPC-157 is a synthetic 15-amino-acid peptide based on a sequence isolated from human gastric juice, studied mostly in rat models of gut, tendon and ligament injury. It is not FDA-approved. Since October 2026, a 503A pharmacy may compound it on a patient-specific prescription under listed conditions. REMEVi does not currently offer BPC-157.
BPC-157 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer BPC-157.
What changed in 2026
On October 30, 2026, the Federal Register published notice of HHS’s interim enforcement-discretion policy for 503A compounding. In plain words: HHS says it does not intend to take enforcement action against a state-licensed 503A pharmacy or federal facility that compounds BPC-157 for an individual patient, as long as every listed condition is met.
For BPC-157 the policy lists four routes: subcutaneous injection, intramuscular injection, oral and topical. All of these conditions apply together:
- A patient-specific prescription from a licensed prescriber.
- Compounding by a state-licensed 503A pharmacy (or a federal facility).
- BPC-157 used by a route listed in the policy’s appendix: subcutaneous, intramuscular, oral or topical.
- Bulk BPC-157 from an FDA-registered facility with a valid certificate of analysis (CoA); the original manufacturer FDA-registered and CGMP-compliant.
- One active ingredient per product. A premixed BPC-157 “blend” does not qualify.
- Oral products: the compounder keeps documentation that the formulation is adequately bioavailable in humans.
- The one device packaged with the drug is an FDA 510(k)-cleared syringe.
- The label reads “This is a compounded drug product. Not for resale.”
- Serious adverse events reported to FDA MedWatch.
The policy is interim, non-binding and revocable. It is not FDA approval and does not add BPC-157 to the 503A bulks list; FDA may propose that later through rulemaking. HHS says it may revisit the policy if a safety signal or product quality issue arises. It covers 503A compounding, not 503B outsourcing facilities. Public comments were open for two weeks after publication (docket HHS-OASH-2026-0496).
Federal Register notice (Oct 30, 2026) · The 2026 policy, explained for patients
How a lawful BPC-157 prescription works
- A licensed prescriber evaluates you: history, medications, and whether BPC-157 is appropriate for you at all.
- If they decide to prescribe, they write a patient-specific prescription naming the route.
- A state-licensed 503A pharmacy compounds it from documented bulk substance (FDA-registered source, valid CoA).
- The product is dispensed to you, labelled “This is a compounded drug product. Not for resale.”
- Any serious adverse event is reported to FDA MedWatch.
A prescription is a clinical decision, not a formality. A provider may decide BPC-157 is not right for you.
Research-grade vials vs compounded prescriptions
Vials sold online labelled for research use are not compounded prescriptions, and the 2026 policy does not cover them. There is no prescriber, no patient-specific label, no licensed pharmacy answerable for what is in the vial, and no adverse-event reporting.
On August 24, 2026, FDA sent warning letters to five online peptide vendors. According to Holland & Knight’s summary, research-use labels did not outweigh evidence that the products were meant for people.
What research exists on BPC-157: mostly animal
Most BPC-157 research is in rats. A 2025 systematic review in HSS Journal included 36 studies: 35 were animal or laboratory studies and one was a human clinical study. The authors rated the evidence low (levels IV and V) and found no clinical safety data in humans.
- Human: a 2021 retrospective chart review of 16 patients who received BPC-157 knee injections, with outcomes collected by phone and no control group.
- Human: a 2025 pilot in which two adults received intravenous BPC-157 over two days, with no control group. Neither knee injection nor IV infusion is a route the 2026 policy lists.
- Human: a registered phase 1 trial of oral BPC-157 tablets (NCT02637284) has no posted results; its status is listed as unknown.
- Animal: rat studies of gut, tendon, ligament and muscle injury models, by injection, in drinking water and as a cream.
A 2025 review in Pharmaceuticals noted that over 80% of indexed BPC-157 records are linked to one research group, and that basic pharmacokinetic profiling is a major gap. Animal findings do not tell you what happens in people.
“Studied in” is not “works for.” No human trial has established that BPC-157 treats any condition.
BPC-157 side effects: what is known
Human side-effect data are close to nonexistent. FDA says it lacks sufficient information to know whether BPC-157 would cause harm in humans, and flags possible immunogenicity and peptide-related impurities. Injection-site reactions are possible with any injection.
BPC-157 dosage: no established human dose
Published doses are rat doses per kilogram of body weight; no human dose has been established for any route. Published protocols vary; a licensed provider sets your dose; never self-dose.
BPC-157 cost
Few programs publish a price for compounded BPC-157, and those that do price it differently (per month, per cycle, or as a membership with medication billed separately). REMEVi does not currently price BPC-157.
Is BPC-157 legal?
Since HHS’s interim policy (Federal Register, October 30, 2026), a state-licensed 503A pharmacy may compound BPC-157 on a patient-specific prescription if every listed condition is met. The policy is interim and revocable, and it does not cover research-use vials sold online. BPC-157 is not FDA-approved.
Is BPC-157 FDA approved?
No. BPC-157 is not FDA-approved for any use. The 2026 HHS policy is enforcement discretion for compounding, not approval: HHS says it does not grant FDA approval or establish clinical safety and effectiveness. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed.
What is BPC-157 used for?
BPC-157 has been studied, almost entirely in rats, in models of stomach and gut injury, tendon, ligament and muscle injury. Human research is limited to a small knee-injection chart review and a two-person IV pilot. No human trial has established that it treats any condition, and it is not FDA-approved.
Can you get BPC-157 with a prescription?
Under the 2026 policy, a licensed prescriber may write a patient-specific prescription that a state-licensed 503A pharmacy compounds, by subcutaneous, intramuscular, oral or topical route, with one active ingredient per product. Whether it is appropriate is the prescriber’s call. REMEVi does not currently offer BPC-157.
Sources
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026) (read November 2, 2026)
- Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Nutritional Outlook (Bigica), Nov 2 2026 — HHS peptide compounding policy: supplement industry implications (read November 2, 2026)
- AJMC (Steinzor), Oct 29 2026 — 5 things to know about HHS’s interim peptide compounding policy (read November 2, 2026)
- Holland & Knight, Oct 16 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) (read November 2, 2026)
- Vasireddi et al., HSS Journal 2025 — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (read November 2, 2026)
- Lee & Padgett, Altern Ther Health Med 2021 — Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (read November 2, 2026)
- Lee & Burgess, Altern Ther Health Med 2025 — Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (read November 2, 2026)
- ClinicalTrials.gov — NCT02637284, PCO-02 (BPC-157 oral tablets) Phase I safety and pharmacokinetics trial, status unknown (read November 2, 2026)
- Józwiak et al., Pharmaceuticals 2025 — Reply to Sikiric et al., comment on “Multifunctionality and Possible Medical Application of the BPC 157 Peptide” (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·